利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.04 秒)

    PYRAZOLOPYRIDINE DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF
    1.
    发明申请
    PYRAZOLOPYRIDINE DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF 审中-公开
    吡唑啉衍生物或其药理学上可接受的盐

    公开(公告)号：US20130331378A1

    公开(公告)日：2013-12-12

    申请号：US13981453

    申请日：2012-01-25

    申请人： Shigeki Seto ,  Kentaro Umei ,  Yosuke Nishigaya ,  Asao Tanioka ,  Tatsuhiro Kondo ,  Atsushi Kondo ,  Kazuya Tatani ,  Naohiro Kawamura

    发明人： Shigeki Seto ,  Kentaro Umei ,  Yosuke Nishigaya ,  Asao Tanioka ,  Tatsuhiro Kondo ,  Atsushi Kondo ,  Kazuya Tatani ,  Naohiro Kawamura

    IPC分类号： C07D471/04

    CPC分类号： C07D471/04

    摘要： A pyrazolopyridine derivative represented by the following formula (I) or a pharmacologically acceptable salt thereof exhibits a strong EP1 receptor antagonistic effect. Thus, the derivative or the pharmacologically acceptable salt is useful as a therapeutic agent for lower urinary tract symptoms (LUTS), particularly, overactive bladder syndrome (OABs), or a prophylactic agent therefor and furthermore, is also useful in the treatment, prevention, or suppression of various pathological conditions in which the EP1 receptor is involved, such as inflammatory disease, pain disease, osteoporosis, and cancer. [A is a benzene ring or the like, Y1 is C1-6 alkylene, R1 is —C(═O)—OZ1 or the like, Z1 is H or the like, R2 is a branched C3-6 alkyl group or the like, R3 is H or the like, R4 is a hydrogen atom or the like, and R5 is a hydrogen atom or the like].

    摘要翻译： 由下式（I）表示的吡唑并吡啶衍生物或其药理学上可接受的盐表现出强烈的EP1受体拮抗作用。 因此，衍生物或药理学上可接受的盐可用作下尿路症状（LUTS），特别是膀胱过度活动症（OAB）或其预防剂的治疗剂，此外，还可用于治疗，预防， 或抑制涉及EP1受体的各种病理状况，例如炎性疾病，疼痛疾病，骨质疏松症和癌症。 [A是苯环等，Y 1是C 1-6亚烷基，R 1是-C（= O）-OZ 1等，Z 1是H等，R 2是支链C 3-6烷基等 ，R3为H等，R4为氢原子等，R5为氢原子等]。

    Fused bicyclic pyridine derivatives as tachykinin receptor antagonists
    6.
    发明申请
    Fused bicyclic pyridine derivatives as tachykinin receptor antagonists 失效
    稠合双环吡啶衍生物作为速激肽受体拮抗剂

    公开(公告)号：US20050107375A1

    公开(公告)日：2005-05-19

    申请号：US10498089

    申请日：2002-12-06

    申请人： Shigeki Seto ,  Asao Tanioka ,  Makoto Ikeda ,  Shigeru Izawa

    发明人： Shigeki Seto ,  Asao Tanioka ,  Makoto Ikeda ,  Shigeru Izawa

    IPC分类号： A61P1/00 ,  A61P1/02 ,  A61P1/04 ,  A61P1/08 ,  A61P11/06 ,  A61P11/14 ,  A61P13/00 ,  A61P13/10 ,  A61P19/02 ,  A61P25/04 ,  A61P25/06 ,  A61P29/00 ,  A61P43/00 ,  C07D498/04 ,  C07D498/02 ,  A61K31/538

    CPC分类号： C07D498/04

    摘要： A novel fused bicyclic pyridine derivative or a salt thereof that acts as a tachykinin receptor antagonist, in particular as an NK1 receptor antagonist, is represented by the following general formula (1): wherein the rings A and B are each a benzene ring which may have 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring); the ring C is a nitrogen-containing ring having a hydrogen atom substituted with a nitrogen atom; R1 and R2 are each independently a hydrogen atom, a C1 to C6 alkyl group, a C1 to C6 alkylsulfonyl group, a C1 to C6 alkylcarbonyl group, or a C1 to C6 alkoxycarbonyl group, or R1 and R2 are bound to one another to form the ring D; m is 1 or 2; n is 2 or 3; and q is an integer from 1 to 4.

    摘要翻译： 用作速激肽受体拮抗剂，特别是作为NK1受体拮抗剂的新型稠合双环吡啶衍生物或其盐由以下通式（1）表示：其中环A和B各自为苯环， 具有1至3个取代基（其中相邻的两个可以彼此结合形成环）; 环C是具有被氮原子取代的氢原子的含氮环; R 1和R 2各自独立地为氢原子，C 1〜C 6烷基，C 1〜C 6烷基， C 1至C 6烷基磺酰基，C 1至C 6烷基羰基，或C C 1 -C 6烷氧基羰基，或R 1和R 2彼此结合形成环D; m为1或2; n为2或3; q为1〜4的整数。

    Fused bicyclic pyridine derivatives as tachykinin receptor antagonists
    8.
    发明授权
    Fused bicyclic pyridine derivatives as tachykinin receptor antagonists 失效
    稠合双环吡啶衍生物作为速激肽受体拮抗剂

    公开(公告)号：US07030107B2

    公开(公告)日：2006-04-18

    申请号：US10498089

    申请日：2002-12-06

    申请人： Shigeki Seto ,  Asao Tanioka ,  Makoto Ikeda ,  Shigeru Izawa

    发明人： Shigeki Seto ,  Asao Tanioka ,  Makoto Ikeda ,  Shigeru Izawa

    IPC分类号： C07D498/04 ,  A61K31/4353 ,  A61K31/4545 ,  A61P1/02 ,  A61P19/02

    CPC分类号： C07D498/04

    摘要： A novel fused bicyclic pyridine derivative or a salt thereof that acts as a tachykinin receptor antagonist, in particular as an NK1 receptor antagonist, is represented by the following general formula (1): wherein the rings A and B are each a benzene ring which may have 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring); the ring C is a nitrogen-containing ring having a hydrogen atom substituted with a nitrogen atom; R1 and R2 are each independently a hydrogen atom, a C1 to C6 alkyl group, a C1 to C6 alkylsulfonyl group, a C1 to C6 alkylcarbonyl group, or a C1 to C6 alkoxycarbonyl group, or R1 and R2 are bound to one another to form the ring D; m is 1 or 2; n is 2 or 3; and q is an integer from 1 to 4.

    摘要翻译： 用作速激肽受体拮抗剂，特别是作为NK1受体拮抗剂的新型稠合双环吡啶衍生物或其盐由以下通式（1）表示：其中环A和B各自为苯环， 具有1至3个取代基（其中相邻的两个可以彼此结合形成环）; 环C是具有被氮原子取代的氢原子的含氮环; R 1和R 2各自独立地为氢原子，C 1〜C 6烷基，C 1〜C 6烷基， C 1至C 6烷基磺酰基，C 1至C 6烷基羰基，或C C 1 -C 6烷氧基羰基，或R 1和R 2彼此结合形成环D; m为1或2; n为2或3; q为1〜4的整数。

    Fused bicyclic pyridine derivative as tachykinin receptor antagonist
    9.
    发明授权
    Fused bicyclic pyridine derivative as tachykinin receptor antagonist 失效
    稠合双环吡啶衍生物作为速激肽受体拮抗剂

    公开(公告)号：US07026309B2

    公开(公告)日：2006-04-11

    申请号：US10508783

    申请日：2003-03-24

    申请人： Shigeki Seto ,  Asao Tanioka ,  Makoto Ikeda ,  Shigeru Izawa

    发明人： Shigeki Seto ,  Asao Tanioka ,  Makoto Ikeda ,  Shigeru Izawa

    IPC分类号： C07D498/04 ,  A61K31/496 ,  A61K31/551 ,  A61K31/553

    CPC分类号： C07D498/04

    摘要： A fused bicyclic pyridine derivative represented by the following general formula (1), or a salt thereof: wherein the rings A and B are each a benzene ring, which may have 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring) that are each independently selected from the group consisting of a halogen atom, a substituted or unsubstituted C1 to C6 alkyl group, and a substituted or unsubstituted C1 to C6 alkoxyl group; R is a C1 to C6 alkylsulfonyl group, a C1 to C6 alkylcarbonyl group, a C1 to C6 alkoxycarbonyl group, or a formyl group; m is 1 or 2; n is 2 or 3; and q is 1 or 2.

    摘要翻译： 由以下通式（1）表示的稠合双环吡啶衍生物或其盐：其中环A和B各自为苯环，其可以具有1至3个取代基（任何相邻的两个可以与一个 另一个形成环），其各自独立地选自卤素原子，取代或未取代的C 1至C 6烷基，以及被取代或未取代的C 1至C 6 未取代的C 1至C 6烷氧基; R是C 1 -C 6烷基磺酰基，C 1 -C 6烷基羰基，C 1 -C 6烷基羰基，C C 1 -C 6烷氧基羰基或甲酰基; m为1或2; n为2或3; q为1或2。